Year None202420232022202120202019201820172016 September 5, 2024 Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference Go to August 27, 2024 Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference Go to August 15, 2024 Medicenna Strengthens Board of Directors with Appointment of Karim Lalji Go to August 1, 2024 Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy Go to June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
September 5, 2024 Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference Go to
August 27, 2024 Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference Go to
August 1, 2024 Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy Go to
June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to
June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to
